Other Natural History Committee members are J Barker, D Becker, S Bennett-Johnson, P Gottlieb, S Harris, E Leschek, K McCants, G Navidi, A Pugliese, M Rewers, K Riley, D Schatz, M Siegelman, D Wilson and A Ziegler.
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results
Article first published online: 24 SEP 2008
© 2008 The Authors Journal compilation © 2008 Blackwell Munksgaard
Volume 10, Issue 2, pages 97–104, March 2009
How to Cite
Mahon, J. L., Sosenko, J. M., Rafkin-Mervis, L., Krause-Steinrauf, H., Lachin, J. M., Thompson, C., Bingley, P. J., Bonifacio, E., Palmer, J. P., Eisenbarth, G. S., Wolfsdorf, J., Skyler, J. S., the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group (2009), The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes, 10: 97–104. doi: 10.1111/j.1399-5448.2008.00464.x
- Issue published online: 23 FEB 2009
- Article first published online: 24 SEP 2008
- Submitted 6 February 2008. Accepted for publication 30 July 2008
- pre-type 1 diabetes;
- natural history
Objectives: TrialNet’s goal to test preventions for type 1 diabetes has created an opportunity to gain new insights into the natural history of pre-type 1 diabetes. The TrialNet Natural History Study (NHS) will assess the predictive value of existing and novel risk markers for type 1 diabetes and will find subjects for prevention trials.
Research design and methods: The NHS is a three-phase, prospective cohort study. In phase 1 (screening), pancreatic autoantibodies (glutamic acid decarboxylase, insulin, ICA-512, and islet cell antibodies) are measured. Phase 2 (baseline risk assessment) includes oral glucose tolerance tests (OGTTs) in antibody-positive subjects and estimation of 5-yr diabetes risks according to the OGTT and number of confirmed positive antibody tests. Phase 3 (follow-up risk assessments) requires OGTTs every 6 months. In phases 2 and 3, samples are collected for future tests of T-lymphocyte function, autoantibody isotypes, RNA gene expression, and proteomics. The primary outcome is diabetes onset.
Results: Of 12 636 relatives screened between March 2004 and December 2006, 605 (4.8%) were positive for at least one biochemical antibody. Of these, 322 were confirmed antibody positive and completed phase 2, of whom 296 subjects were given preliminary 5-yr diabetes risks of <25% (n = 132), ≥25% (n = 36), and ≥50% (n = 128) where the latter two categories represent different subjects based on number of confirmed positive antibodies (2, ≥25%; 3 or more, ≥50%) and/or an abnormal OGTT (≥50%).
Conclusions: The NHS is identifying potential prevention trial subjects and is assembling a large cohort that will provide new natural history information about pre-type 1 diabetes. Follow-up to diabetes will help establish the biological significance and clinical value of novel type 1 diabetes risk markers.